Download PDF
J Knee Surg 2022; 35(01): 096-103
DOI: 10.1055/s-0040-1713114
Original Article

Efficacy of Liposomal Bupivacaine versus Ropivacaine in Adductor Canal Block for Total Knee Arthroplasty

Chang-Hwa Mary Chen 
1   Department of Surgery, St. John's Health Center, Santa Monica, California
,
Andrew G. Yun
1   Department of Surgery, St. John's Health Center, Santa Monica, California
,
Teresa Fan
2   Department of Pharmacy, St. John's Health Center, Santa Monica, California
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Adductor canal block (ACB) is advantageous for postoperative analgesia in total knee arthroplasty (TKA) because it results in minimal motor block. Liposomal bupivacaine (LB) is Food and Drug Administration-approved extended-release formulation of bupivacaine for interscalene peripheral nerve blocks. Its use is increasing in the TKA setting, mainly as a local infiltration agent. We compared the efficacy of ACB using LB versus ropivacaine in TKA. Two cohorts of patients were retrospectively analyzed at a single institution receiving ropivacaine and LB ACB for TKA. Duration of LB ACB, time to first opioid use postrecovery room, amount of opioid use postrecovery room, length of stay (LOS), and average and highest pain scores were collected. A total of 91 and 142 TKA patients received ropivacaine and LB for ACB, respectively. At 8 hours postrecovery room, more patients in the LB group required no opioids compared with the ropivacaine group (p = 0.026). Mean opioid consumption was lower in the LB group than in the ropivacaine group at 8 and 24 hours postrecovery room, although statistical significance was only observed at 8 hours (p = 0.022). The highest pain score for patients in the two groups was not statistically different. The average pain score for patients with a 2-day LOS was higher in the LB group, but average pain scores were similar for patients with 1- and 3-day LOS. Median LOS for the LB and ropivacaine groups was 1 and 2 days, respectively (p < 0.0001). Significantly lower opioid use at 8 hours postrecovery room was seen in the LB group compared with the ropivacaine group. There was no difference in opioid use at 24 and 48 hours. There was also no advantage with LB ACB in decreasing pain scores. However, the LB ACB group demonstrated a significantly shorter LOS compared with the ropivacaine ACB group.

Keywords

liposomal bupivacaine - adductor canal block - total knee arthroplasty


Publication History

Received: 31 October 2019

Accepted: 02 May 2020

Article published online:
24 June 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Nader A, Kendall MC, Manning DW. et al. Single-dose adductor canal block with local infiltrative analgesia compared with local infiltrate analgesia after total knee arthroplasty: a randomized, double-blind, placebo-controlled trial. Reg Anesth Pain Med 2016; 41 (06) 678-684
    CrossrefPubMedGoogle Scholar
  • 2 Jæger P, Jenstrup MT, Lund J. et al. Optimal volume of local anaesthetic for adductor canal block: using the continual reassessment method to estimate ED95. Br J Anaesth 2015; 115 (06) 920-926
    CrossrefPubMedGoogle Scholar
  • 3 Jæger P, Koscielniak-Nielsen ZJ, Hilsted KL, Fabritius ML, Dahl JB. Adductor canal block with 10 mL versus 30 mL local anesthetics and quadriceps strength: a paired, blinded, randomized study in healthy volunteers. Reg Anesth Pain Med 2015; 40 (05) 553-558
    CrossrefPubMedGoogle Scholar
  • 4 Jaeger P, Nielsen ZJ, Henningsen MH, Hilsted KL, Mathiesen O, Dahl JB. Adductor canal block versus femoral nerve block and quadriceps strength: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Anesthesiology 2013; 118 (02) 409-415
    CrossrefPubMedGoogle Scholar
  • 5 Kim DH, Lin Y, Goytizolo EA. et al. Adductor canal block versus femoral nerve block for total knee arthroplasty: a prospective, randomized, controlled trial. Anesthesiology 2014; 120 (03) 540-550
    CrossrefPubMedGoogle Scholar
  • 6 Grevstad U, Mathiesen O, Valentiner LS, Jaeger P, Hilsted KL, Dahl JB. Effect of adductor canal block versus femoral nerve block on quadriceps strength, mobilization, and pain after total knee arthroplasty: a randomized, blinded study. Reg Anesth Pain Med 2015; 40 (01) 3-10
    CrossrefPubMedGoogle Scholar
  • 7 Jenstrup MT, Jæger P, Lund J. et al. Effects of adductor-canal-blockade on pain and ambulation after total knee arthroplasty: a randomized study. Acta Anaesthesiol Scand 2012; 56 (03) 357-364
    CrossrefPubMedGoogle Scholar
  • 8 Gwam CU, Mistry JB, Khlopas A. et al. Does addition of multimodal periarticular analgesia to adductor canal block improve lengths of stay, pain, discharge status, and opioid use after total knee arthroplasty?. J Arthroplasty 2017; 32 (05) 1470-1473
    CrossrefPubMedGoogle Scholar
  • 9 Fanelli G, Casati A, Beccaria P. et al. A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg 1998; 87 (03) 597-600
    CrossrefPubMedGoogle Scholar
  • 10 Kuthiala G, Chaudhary G. Ropivacaine: a review of its pharmacology and clinical use. Indian J Anaesth 2011; 55 (02) 104-110
    CrossrefPubMedGoogle Scholar
  • 11 Kosel J, Bobik P, Siemiątkowski A. Buprenorphine added to bupivacaine prolongs femoral nerve block duration and improves analgesia in patients undergoing primary total knee arthroplasty-a randomised prospective double-blind study. J Arthroplasty 2015; 30 (02) 320-324
    CrossrefPubMedGoogle Scholar
  • 12 Ali QE, Manjunatha L, Amir SH, Jamil S, Quadir A. Efficacy of clonidine as an adjuvant to ropivacaine in supraclavicular brachial plexus block: a prospective study. Indian J Anaesth 2014; 58 (06) 709-713
    CrossrefPubMedGoogle Scholar
  • 13 Andersen JH, Jaeger P, Sonne TL, Dahl JB, Mathiesen O, Grevstad U. Clonidine used as a perineural adjuvant to ropivacaine, does not prolong the duration of sensory block when controlling for systemic effects: a paired, blinded, randomized trial in healthy volunteers. PLoS ONE 2017; 12 (09) e0181351
    CrossrefPubMedGoogle Scholar
  • 14 Erlacher W, Schuschnig C, Orlicek F, Marhofer P, Koinig H, Kapral S. The effects of clonidine on ropivacaine 0.75% in axillary perivascular brachial plexus block. Acta Anaesthesiol Scand 2000; 44 (01) 53-57
    CrossrefPubMedGoogle Scholar
  • 15 Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth 2013; 110 (06) 915-925
    CrossrefPubMedGoogle Scholar
  • 16 Ellis II TA, Hammoud H, Dela Merced P. et al. Multimodal clinical pathway with adductor canal block decreases hospital length of stay, improves pain control, and reduces opioid consumption in total knee arthroplasty patients: a retrospective review. J Arthroplasty 2018; 33 (08) 2440-2448
    CrossrefPubMedGoogle Scholar
  • 17 Huynh TM, Marret E, Bonnet F. Combination of dexamethasone and local anaesthetic solution in peripheral nerve blocks: a meta-analysis of randomised controlled trials. Eur J Anaesthesiol 2015; 32 (11) 751-758
    CrossrefPubMedGoogle Scholar
  • 18 Chahar P, Cummings III KC. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res 2012; 5: 257-264
    Google Scholar
  • 19 Administration UFaD. FDA Label Approved on 10/28/2011 for Liposomal Bupivacaine. In: FDA, ed. Silver Spring, MD. 2012 Accessed May 14, 2020 at: http://investor.pacira.com/news-releases/news-release-details/fda-posts-briefing-documents-advisory-meeting-reviewing-snda-0
  • 20 Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum 2011; 54 (12) 1552-1559
    CrossrefPubMedGoogle Scholar
  • 21 Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther 2011; 28 (09) 776-788
    CrossrefPubMedGoogle Scholar
  • 22 Sakamoto B, Keiser S, Meldrum R, Harker G, Freese A. Efficacy of liposomal bupivacaine infiltration on the management of total knee arthroplasty. JAMA 2017; 152 (01) 90-95
    PubMedGoogle Scholar
  • 23 Wang Y, Klein MS, Mathis S, Fahim G. Adductor canal block with bupivacaine liposome versus ropivacaine pain ball for pain control in total knee arthroplasty: a Retrospective Cohort Study. Ann Pharmacother 2016; 50 (03) 194-202
    CrossrefPubMedGoogle Scholar
  • 24 Phillips J, Doshi A. Effects of liposomal bupivacaine with adductor canal block on pain and functional outcomes in patients undergoing total knee arthroplasty. Ann Pharmacother 2016; 50 (09) 706-711
    CrossrefPubMedGoogle Scholar
  • 25 Kuang MJ, Du Y, Ma JX, He W, Fu L, Ma XL. The efficacy of liposomal bupivacaine using periarticular injection in total knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2017; 32 (04) 1395-1402
    CrossrefPubMedGoogle Scholar
  • 26 Richard BM, Newton P, Ott LR. et al. The safety of EXPAREL ® (bupivacaine liposome injectable suspension) administered by peripheral nerve block in rabbits and dogs. J Drug Deliv 2012; 2012: 962101
    CrossrefPubMedGoogle Scholar
  • 27 Administration UFaD. LB Briefing Document. Pacira Pharamceutical, INC. In: Meeting FAC, ed. 14. 2018. Accessed May 14, 2020 at: http://investor.pacira.com/news-releases/news-release-details/fda-posts-briefing-documents-advisory-meeting-reviewing-snda-0
    Google Scholar
  • 28 Lakra A, Grosso M, Jennings EL, Cooper HJ, Shah RP, Geller JA. Improved pain control with adductor canal block using liposomal bupivacaine after total knee replacement: a retrospective cohort study. Arthroplast Today 2019; 5 (03) 325-328
    CrossrefPubMedGoogle Scholar
  • 29 Kirkpatrick JD, Sites BD, Antonakakis JG. Preliminary experience with a new approach to performing an ultrasound-guided saphenous nerve block in the mid to proximal femur. Reg Anesth Pain Med 2010; 35 (02) 222-223
    CrossrefPubMedGoogle Scholar
  • 30 Pichler L, Poeran J, Zubizarreta N. et al. Liposomal bupivacaine does not reduce inpatient opioid prescription or related complications after knee arthroplasty: a database analysis. Anesthesiology. Anesthesiology 2018; 129 (04) 689-699
    CrossrefPubMedGoogle Scholar
  • 31 Hadzic A, Minkowitz HS, Melson TI. et al. Liposome bupivacaine femoral nerve block for postsurgical analgesia after total knee arthroplasty. Anesthesiology 2016; 124 (06) 1372-1383
    CrossrefPubMedGoogle Scholar
  • 32 Vickers AJ. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. BMC Med Res Methodol 2005; 5: 35
    CrossrefPubMedGoogle Scholar
  • 33 EXPAREL. . (bupivacaine liposome injectable suspension) [package insert]. Pacira Pharmaceuticals, Inc. San Diego, CA. 2018. Accessed May 14, 2020 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022496s9lbl.pdf
  • 34 Singh PM, Borle A, Trikha A, Michos L, Sinha A, Goudra B. Role of periarticular liposomal bupivacaine infiltration in patients undergoing total knee arthroplasty – a meta-analysis of comparative trials. J Arthroplasty 2017; 32 (02) 675-688.e1
    CrossrefPubMedGoogle Scholar